DK0903345T3 - Krystalform af N-(4-trifluormethylphenyl)-5-methyl-isoxazol-4-carboxamid - Google Patents

Krystalform af N-(4-trifluormethylphenyl)-5-methyl-isoxazol-4-carboxamid

Info

Publication number
DK0903345T3
DK0903345T3 DK98114373T DK98114373T DK0903345T3 DK 0903345 T3 DK0903345 T3 DK 0903345T3 DK 98114373 T DK98114373 T DK 98114373T DK 98114373 T DK98114373 T DK 98114373T DK 0903345 T3 DK0903345 T3 DK 0903345T3
Authority
DK
Denmark
Prior art keywords
trifluoromethylphenyl
isoxazole
carboxamide
methyl
crystal form
Prior art date
Application number
DK98114373T
Other languages
Danish (da)
English (en)
Inventor
Holger Dr Faasch
Udo Dr Hedtmann
Uwe Dr Westenfelder
Erich Dr Paulus
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19734438A external-priority patent/DE19734438A1/de
Priority claimed from DE1997156093 external-priority patent/DE19756093A1/de
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Application granted granted Critical
Publication of DK0903345T3 publication Critical patent/DK0903345T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK98114373T 1997-08-08 1998-07-31 Krystalform af N-(4-trifluormethylphenyl)-5-methyl-isoxazol-4-carboxamid DK0903345T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19734438A DE19734438A1 (de) 1997-08-08 1997-08-08 Kristallform von N-(4-Trifluormethylphenyl)-5-methyl-isoxazole-4-carboxamid
DE1997156093 DE19756093A1 (de) 1997-12-17 1997-12-17 Verfahren zur Herstellung einer Kristallform von N-(4-Trifluormethylphenyl)-5-methyl-isoxazole-4-carboxamid

Publications (1)

Publication Number Publication Date
DK0903345T3 true DK0903345T3 (da) 2000-10-23

Family

ID=26038983

Family Applications (2)

Application Number Title Priority Date Filing Date
DK98114373T DK0903345T3 (da) 1997-08-08 1998-07-31 Krystalform af N-(4-trifluormethylphenyl)-5-methyl-isoxazol-4-carboxamid
DK99117098T DK0987256T3 (da) 1997-08-08 1998-07-31 Krystalform af N-(4-trifluormethylphenyl)-5-methylisoxazol-4-carboxylsyreamid

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK99117098T DK0987256T3 (da) 1997-08-08 1998-07-31 Krystalform af N-(4-trifluormethylphenyl)-5-methylisoxazol-4-carboxylsyreamid

Country Status (28)

Country Link
US (5) US6060494A (no)
EP (2) EP0903345B1 (no)
JP (2) JPH11124372A (no)
KR (2) KR100544041B1 (no)
CN (2) CN1181064C (no)
AR (1) AR015418A1 (no)
AT (2) ATE207065T1 (no)
AU (1) AU752764B2 (no)
BR (1) BR9806568A (no)
CA (1) CA2245267C (no)
CZ (3) CZ292943B6 (no)
DE (2) DE59801792D1 (no)
DK (2) DK0903345T3 (no)
ES (2) ES2166205T3 (no)
GR (1) GR3034814T3 (no)
HK (2) HK1017681A1 (no)
HU (2) HU229232B1 (no)
ID (1) ID20667A (no)
IL (1) IL125671A (no)
NO (1) NO310871B1 (no)
NZ (1) NZ331270A (no)
PL (1) PL192126B1 (no)
PT (2) PT903345E (no)
RU (1) RU2224753C2 (no)
SK (2) SK282641B6 (no)
TR (2) TR199801513A3 (no)
TW (1) TW593288B (no)
UA (1) UA54411C2 (no)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE207065T1 (de) * 1997-08-08 2001-11-15 Aventis Pharma Gmbh Kristallform von n-(4-trifluormethylphenyl)-5- methylisoxazol-4-carbonsäureamid
DE19908527C2 (de) 1999-02-26 2001-08-30 Aventis Pharma Gmbh Verfahren zur Kristallisation von N-(4-Trifluormethylphenyl)-5-methyl-isoxazol-4-carboxamid
CN1411373A (zh) * 1999-12-16 2003-04-16 特瓦制药工业有限公司 制备来氟米特的新方法和新晶形的来氟米特
ATE292966T1 (de) * 2000-02-15 2005-04-15 Teva Pharma Methode zur synthetisierung von leflunomid
WO2002040458A1 (fr) * 2000-11-17 2002-05-23 Takeda Chemical Industries, Ltd. Derives d'isoxazole
GB0123571D0 (en) 2001-04-05 2001-11-21 Aventis Pharm Prod Inc Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis
US7429593B2 (en) 2001-09-14 2008-09-30 Shionogi & Co., Ltd. Utilities of amide compounds
US20050158371A1 (en) * 2002-02-12 2005-07-21 Sumitomo Pharmaceuticals Co., Ltd. Novel external agent
JPWO2003068239A1 (ja) * 2002-02-12 2005-06-02 住友製薬株式会社 新規外用剤
WO2004108700A1 (en) * 2003-03-12 2004-12-16 Teva Gyogyszergyar Reszvenytarsasag Processes for preparation of polymorphic forms of desloratadine
US20060135547A1 (en) * 2003-03-12 2006-06-22 Toth Zoltan G Stable pharmaceutical compositions of desloratadine and processes for preparation of polymorphic forms of desloratadine
JP4223428B2 (ja) * 2004-03-31 2009-02-12 富士通メディアデバイス株式会社 フィルタおよびその製造方法
WO2007067710A1 (en) * 2005-12-08 2007-06-14 Amphora Discovery Corporation Certain chemical entities, compositions, and methods for modulating trpv1
CN101143834B (zh) * 2006-09-15 2010-09-08 欣凯医药化工中间体（上海）有限公司 N-(4-三氟甲基苯)-2-氰基-3-羟基丁烯酰胺钠盐的多晶型及其制备方法
EP2262790B1 (en) * 2008-03-10 2017-06-07 Takeda Pharmaceutical Company Limited Crystal of benzimidazole compound
PE20121478A1 (es) 2009-09-18 2012-11-12 Sanofi Sa Formulaciones en comprimido de teriflunomida: "(4'-trifluorometilfenil) amida del acido (z)-2-ciano-3-hidroxibut-2-enoico con estabilidad mejorada
CN103977594B (zh) * 2014-06-03 2016-02-17 江苏九九久科技股份有限公司 一种结晶方法
US9895370B2 (en) * 2015-11-19 2018-02-20 Pharmedix.Co., Ltd Pharmaceutical composition for preventing or treating of cirrhosis of liver comprising G protein coupled receptor 119 ligand as an active ingredient
CN109180599A (zh) * 2018-09-03 2019-01-11 深圳市新阳唯康科技有限公司 一种来氟米特新晶型化合物及其制备方法
CN112898215B (zh) * 2021-02-04 2022-11-08 美罗药业股份有限公司 一种来氟米特晶型i的制备方法
CN114716388B (zh) * 2021-11-04 2024-02-13 江苏冠军科技集团股份有限公司 一种磺胺-银化合物及其制备方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL178596C (nl) * 1975-06-05 1986-04-16 Hoechst Ag Werkwijze voor het bereiden van een geneesmiddel met antiflogistische en/of analgetische werking, alsmede werkwijze voor het bereiden van daarin als geneeskrachtige verbindingen te gebruiken 5-methylisoxazool-4-carbonzuuraniliden.
NL186239B (nl) * 1975-06-05 Hoechst Ag Werkwijze voor de bereiding van een geneesmiddel met antiflogistische en/of analgetische werking, alsmede werkwijze voor de bereiding van een 2-hydroxyethylideencyaanazijnzuuranilide geschikt voor toepassing bij deze werkwijze.
DE2524959C2 (de) * 1975-06-05 1983-02-10 Hoechst Ag, 6000 Frankfurt 5-Methyl-isoxazol-4-carbonsäureanilide, Verfahren zu ihrer Herstellung, diese Verbindungen enthaltende Mittel
DE2525959A1 (de) * 1975-06-11 1977-02-10 Focke Pfuhl Verpack Automat Verpackung fuer zigaretten, zigarillos etc.
DE2854439A1 (de) * 1978-12-16 1980-07-03 Hoechst Ag Ein isoxazolderivat, verfahren zu seiner herstellung, diese verbindung enthaltende mittel und verwendung
IL63968A (en) * 1980-10-01 1985-10-31 Glaxo Group Ltd Form 2 ranitidine hydrochloride,its preparation and pharmaceutical compositions containing it
US4935434A (en) * 1988-01-26 1990-06-19 Bristol-Myers Company Antiarthritic isoxazole-4-carboxamides
US5583150A (en) * 1989-08-18 1996-12-10 Alcon Laboratories, Inc. 5-methyl-isoxazole-4-carboxylic acid anilides and 2-hydroxyethylidene-cyano acetic anilides for the treatment of ocular diseases
DK0527736T3 (da) * 1990-05-18 1997-10-20 Hoechst Ag Isoxazol-4-carboxylsyreamider og hydroxyalkyliden-cyanoacetamider, lægemidler indeholdende disse forbindelser og anvendelsen af disse lægemidler.
DE4127737A1 (de) * 1991-08-22 1993-02-25 Hoechst Ag Arzneimittel zur behandlung von abstossungsreaktionen bei organverpflanzungen
GB9209330D0 (en) * 1992-04-30 1992-06-17 Roussel Lab Ltd Chemical compounds
EP0607775B1 (de) * 1993-01-08 1998-12-09 Hoechst Aktiengesellschaft Verwendung von Leflunomid zur Hemmung von Interleukin 1 beta
ATE174220T1 (de) * 1993-01-08 1998-12-15 Hoechst Ag Verwendung von leflunomid zur hemmung von interleukin 8
ATE174219T1 (de) * 1993-01-08 1998-12-15 Hoechst Ag Verwendung von leflunomid zur hemmung von tumornekrosefaktor alpha
TW314467B (no) 1993-03-31 1997-09-01 Hoechst Ag
GB9320299D0 (en) * 1993-10-01 1993-11-17 Roussel Lab Ltd Isoxazole derivatives
US5610173A (en) * 1994-01-07 1997-03-11 Sugen, Inc. Formulations for lipophilic compounds
US5814649A (en) * 1994-10-17 1998-09-29 Hoechst Pharmaceuticals & Chemicals K.K. Preventive and remedy for type 1 allergic diseases
AR001982A1 (es) * 1995-02-06 1998-01-07 Smithkline Beecham Plc Clorhidrato de paroxetina anhidratado, y procedimiento para su preparacion
DE19539638A1 (de) * 1995-10-25 1997-04-30 Hoechst Ag Die Verwendung von Isoxazol- und Crotonsäureamidderivaten zur Behandlung von Krebserkrankungen
US6316479B1 (en) * 1997-05-19 2001-11-13 Sugen, Inc. Isoxazole-4-carboxamide compounds active against protein tryosine kinase related disorders
HRP980291A2 (en) * 1997-06-16 1999-04-30 Lin-Hua Zhang Crystalline roxifiban
ATE207065T1 (de) * 1997-08-08 2001-11-15 Aventis Pharma Gmbh Kristallform von n-(4-trifluormethylphenyl)-5- methylisoxazol-4-carbonsäureamid
US6096770A (en) * 1998-08-03 2000-08-01 American Home Products Corporation Anthranilic acid analogs
DE19908527C2 (de) * 1999-02-26 2001-08-30 Aventis Pharma Gmbh Verfahren zur Kristallisation von N-(4-Trifluormethylphenyl)-5-methyl-isoxazol-4-carboxamid
CN1411373A (zh) * 1999-12-16 2003-04-16 特瓦制药工业有限公司 制备来氟米特的新方法和新晶形的来氟米特
ATE292966T1 (de) * 2000-02-15 2005-04-15 Teva Pharma Methode zur synthetisierung von leflunomid
US6727272B1 (en) * 2002-07-15 2004-04-27 Unitech Pharmaceuticals, Inc. Leflunomide analogs for treating rheumatoid arthritis

Also Published As

Publication number Publication date
NO983632D0 (no) 1998-08-07
PL192126B1 (pl) 2006-09-29
HU225870B1 (en) 2007-11-28
IL125671A (en) 2002-11-10
KR100588254B1 (ko) 2006-06-12
NZ331270A (en) 2000-04-28
US20040204465A1 (en) 2004-10-14
CZ301426B6 (cs) 2010-02-24
GR3034814T3 (en) 2001-02-28
SK282641B6 (sk) 2002-10-08
CN1208034A (zh) 1999-02-17
CN1089759C (zh) 2002-08-28
CZ246898A3 (cs) 1999-02-17
IL125671A0 (en) 1999-04-11
US6900334B2 (en) 2005-05-31
EP0987256B1 (de) 2001-10-17
CZ301514B6 (cs) 2010-03-31
TR199801513A2 (xx) 1999-02-22
SK285216B6 (sk) 2006-09-07
HK1049481B (zh) 2005-07-08
EP0903345B1 (de) 2000-10-04
JPH11124372A (ja) 1999-05-11
ATE207065T1 (de) 2001-11-15
KR20050077498A (ko) 2005-08-02
US20030166945A1 (en) 2003-09-04
CA2245267C (en) 2008-12-23
HUP9801844A3 (en) 2000-04-28
DE59800287D1 (de) 2000-11-09
ATE196764T1 (de) 2000-10-15
KR100544041B1 (ko) 2006-09-18
HU0700190D0 (en) 2007-05-02
HK1049481A1 (en) 2003-05-16
US6060494A (en) 2000-05-09
TW593288B (en) 2004-06-21
TR200600582A1 (tr) 2006-08-21
ES2150808T3 (es) 2000-12-01
EP0903345A1 (de) 1999-03-24
JP2009280604A (ja) 2009-12-03
RU2224753C2 (ru) 2004-02-27
PL327901A1 (en) 1999-02-15
SK105898A3 (en) 1999-02-11
KR19990023433A (ko) 1999-03-25
US6552202B2 (en) 2003-04-22
ID20667A (id) 1999-02-11
HK1017681A1 (en) 1999-11-26
NO983632L (no) 1999-02-09
CN1181064C (zh) 2004-12-22
CN1373126A (zh) 2002-10-09
AU7887098A (en) 1999-02-18
US6995272B2 (en) 2006-02-07
HU229232B1 (en) 2013-09-30
HUP9801844A2 (hu) 2000-02-28
US6221891B1 (en) 2001-04-24
US20030027851A1 (en) 2003-02-06
NO310871B1 (no) 2001-09-10
TR199801513A3 (tr) 1999-02-22
AR015418A1 (es) 2001-05-02
DK0987256T3 (da) 2002-02-11
PT987256E (pt) 2002-03-28
UA54411C2 (uk) 2003-03-17
CA2245267A1 (en) 1999-02-08
CZ292943B6 (cs) 2004-01-14
DE59801792D1 (de) 2001-11-22
EP0987256A1 (de) 2000-03-22
AU752764B2 (en) 2002-09-26
BR9806568A (pt) 2000-05-16
ES2166205T3 (es) 2002-04-01
PT903345E (pt) 2001-01-31
HU9801844D0 (en) 1998-10-28

Similar Documents

Publication Publication Date Title
DK0903345T3 (da) Krystalform af N-(4-trifluormethylphenyl)-5-methyl-isoxazol-4-carboxamid
DK1445259T3 (da) Anvendelse af krystalformer for 2-methyl-thieno-benzodiazepin
DK0923585T3 (da) Phosphinatbaserede inhibitorer af matrixmetalloproteinaser
CY2012029I2 (el) Nεα μορφη της 5-ομεπραζολης
DK0998473T3 (da) Krystalmodifikation af et N-phenyl-2-pyrimidinaminderivat, fremgangsmåder til fremstilling deraf samt dets anvendelse
DK0908449T3 (da) Fremstilling af carotenoider
DE69928195D1 (de) Komplettierung von Untrerdruck-Bohrlöchern
DK38293D0 (da) Fremstilling af proteiner
NO983666L (no) Krystallmodifikasjon av et farmas°ytisk middel
DK1102747T3 (da) Krystalformer af osenetant
DE69800559D1 (de) Ferrielektrische Flüssigkristallverbindung
DE69927626D1 (de) Ausführung von Permutationen
DE69823908D1 (de) Einkristallziehvorrichtung
ID23885A (id) Bentuk-bentuk polimorf baru dari cypamfylline
DK0689577T3 (da) Anvendelse af ferroncen
DK82592D0 (da) Fremstilling af proteiner
IS5426A (is) Fjölbrigðaform af dófetilíði
DE69528320D1 (de) Optische Frequenzmischanordnung
DK0859001T3 (da) Fremstilling af oxazolderivater
DK0927163T3 (da) Fremstilling af 1-butyl-4-piperidinylmethylamin
FI974508A (fi) Iskuja synnyttävä laite
DK0882722T3 (da) Fremstilling af alpha-tocopherol
DK0589626T3 (da) Fremstilling af beta-methylcarbapenem-mellemprodukter
IL139438A0 (en) Crystal form of n- (4-trifluoromethylphenyl)-5-methylisoxazole-4-carboxamide
ZA987127B (en) Crystal form of N-(4-trifuloromethylphenyl)-5-methylisoxazole-4-carboxamide